Management Team

 

William Moffitt 

President and Chief Executive Officer

Mr. Moffitt became president and CEO of Nanosphere in 2004. Moffitt is a 30+ year veteran of the diagnostics and medical device industry, having spent the last 20 years developing novel technologies into products and solutions that have helped shape the industry and generate significant shareholder value.  Prior to Nanosphere, he served as president and CEO of i-STAT Corporation, a developer, manufacturer and marketer of diagnostic products that pioneered the point-of-care blood analysis market. Moffitt led i-STAT from its early stage to commercialization and from the company's IPO in 1992 to its acquisition by Abbott Laboratories in 2003. Prior to i-STAT, Moffitt held increasingly responsible executive positions from 1973 through 1989 with Baxter Healthcare Corporation, a $7 billion manufacturer and distributor of healthcare products, and American Hospital Supply Corporation, a $3.5 billion diversified manufacturer and distributor of healthcare products, which Baxter acquired in 1985. Moffitt earned a B.S. in zoology from Duke University.
 
 

Roger Moody

Vice President of Finance, Treasurer and Chief Financial Officer 

Roger Moody has more than 17 years of experience in leading finance, corporate development and operations for high growth healthcare and technology companies.  Previously, Mr. Moody spent six years as COO and CFO at Medsn, a medical education company, where he led the company’s growth from a development stage venture to a global leader in scientific communications.  Mr. Moody also served as CFO and led corporate development for two venture backed companies sold to strategic partners.  Additionally, Mr. Moody provided M&A and strategic advisory services to technology and healthcare companies for Volpe Brown Whelan & Company.  Mr. Moody began his career at IBM where he contributed to the rapid growth of IBM Global Services.  Mr. Moody received his BS from Syracuse University and his MBA from the University of Chicago, Graduate School of Business.
 
 

Bill Athenson

Vice President of International Marketing and Business Development 

Mr. Athenson joined Nanosphere in January 2002.  Mr. Athenson brings to Nanosphere more than 21 years of healthcare experience in clinical diagnostics, medical devices and information technology with Fortune 500 companies such as Baxter, American Scientific Products, Allegiance Healthcare and two start-up technology companies.  Before joining Nanosphere in January 2002, Mr. Athenson served as General Manager for Allegiance Healthcare with P&L responsibility for a $120 million revenue base.  At Allegiance and in previous leadership positions at Baxter Diagnostics and American Scientific Products, he maintained a consistent track record for leading business development, consulting, and operations teams which consistently achieved double-digit revenue and EBITDA growth in the clinical-laboratory and point-of-care markets.  Most recently he headed business development teams in two new technology start-up companies achieving successful launches. Mr. Athenson holds an M.B.A. from Kellogg School of Business and a bachelor's degree from Fordham University. 

 

Mark Del Vecchio 

Vice President of Regulatory Affairs

Mark Del Vecchio joined Nanosphere in 2011 as Vice President of Regulatory Affairs with over 20 years of clinical and regulatory experience in the biotechnology and molecular in-vitro diagnostic (IVD) industries.  Prior to coming to Nanosphere, Mr. Del Vecchio served as Vice President of Regulatory Affairs for LipoScience, Vice President of Regulatory and Clinical Affairs for Digene Corporation (now Qiagen), Director of Regulatory Affairs in the Food, Drug, Medical Device, and Agriculture practice at Hogan and Hartson, LLP, (now Hogan Lovells) and Manager of Clinical Affairs for Roche Molecular Systems.  In these positions, Mr. Del Vecchio has acquired extensive experience interacting with the US Food and Drug Administration (FDA) Office of In-Vitro Diagnostic Device Evaluation and Safety (OIVD) and several international regulatory authorities, having worked predominantly with IVD’s on the leading-edge of diagnostic technology.  Mr. Del Vecchio also served as Special Representative to the AdvaMed Board of Directors and as a member of the AdvaMed Diagnostic Sector Technology and Regulation Sub-committee, the Diagnostic Task Force (DTF), and the Genetics/Molecular IVD sub-committee of the DTF.  Mr. Del Vecchio holds a Bachelor of Science degree in Biochemistry from the University of Scranton.

 

Winton Gibbons 

Senior Vice President of Business Development 

Winton G. Gibbons joined Nanosphere midyear 2007 as Senior Vice President of Business Development. From 2005 to 2007, he was Senior Vice President for Strategic and Global Product Marketing at Biosite (now Inverness Medical). For the period of 1997 through 2005, he was a sell-side equity analyst for the investment firm of William Blair & Company, L.L.C., covering diagnostic, life science and biotech biotechnology companies, and during which he became a Principal, as well as Group Head for healthcare. Prior to that position, from 1994 to 1997, Mr. Gibbons was Vice President of Strategy and Business Development for the Patient Care Division of Boehringer Mannheim Diagnostics (now Roche Diagnostics). He has also been a Director of Management Services at Merck & Co., a consultant and manager at McKinsey & Company, and held marketing and sales positions at Conoco Chemicals, where he began his career. Mr. Gibbons holds an M.B.A. in Finance and Business Policy from the University of Chicago—Graduate School of Business and a Bachelor of Science degree in Chemistry from Duke University.
 

Michael McGarrity

Vice President of Sales and Marketing and Chief Commercial Officer

Mr. McGarrity, who has more than 17 years of sales and marketing experience in the medical device industry, joined Nanosphere after 13 years with Stryker Corporation. He served in leadership roles in marketing and strategic development, most recently as vice president of marketing for Stryker Instruments, a $700 million division of the $4.3 billion Stryker Corporation. In this position, McGarrity's marketing and business development acumen guided the company into markets such as post-operative pain management, waste management and interventional pain management which now account for more than 20 percent of the division's revenue. He also had executive general management responsibility for a newly created business focused on interventional pain management. McGarrity is a graduate of the University of Notre Dame and began his career in commercial banking in Chicago.
 

Tim Patno 

Vice President of Research and Development, Chief Technology Officer 

Mr. Patno has been at Nanosphere since 2001. Mr. Patno led the development efforts of the Verigene® Systems and the Verigene® genomic assays. Additionally, he led the design efforts for the consumable manufacturing operations and has operationally led the microarray and consumable manufacturing teams since 2008. In 2009 he became responsible for Nanosphere's other manufacturing operations. Prior to joining Nanosphere, Mr. Patno spent 9 years leading the System Engineering Groups for Baxter Fenwal's Amicus® (blood cell) Separator. He was part of this team from product conception through a successful global market launch with annual global product sales of approximately $115M in 2001. From 1988 to 1992, Mr. Patno learned System Engineering and system integration skills working at Hughes Aircraft Company's Space & Communications Group working on the HS601 spacecraft bus and the UHF F/O satellite system. Mr. Patno has degrees in General Engineering, BS, from the University of Illinois - Urbana/Champaign and Electrical Engineering, MS, from the University of Southern California. Mr. Patno was a Hughes Fellow at USC and an Evans Scholar at the University of Illinois.